Skip to main content

Grafa News and Videos — Page 1220

Latest

Grafa

Hovnanian reports narrow Q2 loss as rising home contracts outpace margin pressures

Hovnanian Enterprises (NYSE:HOV) reported a small net loss for its second fiscal quarter that nevertheless came in ahead of internal operating guidance, as resilient homebuyer traffic helped the national homebuilder mitigate ongoing margin compression and affordability hurdles.

Read more: Hovnanian reports narrow Q2 loss as rising home contracts outpace margin pressures
Grafa
Health

Cosmos Health revenue rises 31% to record as U.S. expansion offsets widening net loss

Cosmos Health (NASDAQ:COSM) generated record revenue in the first quarter of 2026, driven by sustained distribution gains and market expansions, even as a shifting business mix and operational investments weighed on bottom-line profitability.

Read more: Cosmos Health revenue rises 31% to record as U.S. expansion offsets widening net loss
Grafa

Immix Biopharma reports 95% complete response rate in next-gen amyloidosis trial

Immix Biopharma (NASDAQ:IMMX) announced a highly favorable interim update from its ongoing registrational Phase 2 NEXICART-2 clinical trial, showing that its investigational CAR-T cell therapy, NXC-201, achieved a 95% complete response rate in patients with relapsed or refractory AL Amyloidosis.

Read more: Immix Biopharma reports 95% complete response rate in next-gen amyloidosis trial
Grafa

China approves HUTCHMED and Innovent combo therapy for advanced kidney cancer

HUTCHMED (NASDAQ:HCM) and Innovent Biologics jointly announced that China’s National Medical Products Administration has approved the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) for the treatment of adults with advanced kidney cancer.

Read more: China approves HUTCHMED and Innovent combo therapy for advanced kidney cancer
Grafa
Agriculture

Origin Agritech revenue drops 31.9% as deep cost cuts trim first-half loss

Origin Agritech (NASDAQ:SEED) reported a 31.9% decline in revenue for the first half of fiscal 2026, reflecting a deliberate structural transition within its commercial seed portfolio, though aggressive corporate cost-saving initiatives allowed the company to significantly narrow its net loss.

Read more: Origin Agritech revenue drops 31.9% as deep cost cuts trim first-half loss

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift